Sharianne G Louie

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo.

M. Heinrich, A. Town, T. Abrams, 2003, Blood.

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.

Randy Allred, Hubert Serve, Wolfgang E Berdel, 2005, Blood.

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Juthamas Sukbuntherng, Robert A Blake, Guangmin Li, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.